Literature DB >> 20237023

Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease.

Koen Van Laere1, Kristien Clerinx, Eduard D'Hondt, Tjibbe de Groot, Wim Vandenberghe.   

Abstract

UNLABELLED: Striatal dopamine D(2) receptor (D2R) PET has been proposed to differentiate between Parkinson disease (PD) and multiple-system atrophy with predominant parkinsonism (MSA-P). However, considerable overlap in striatal D(2) binding may exist between PD and MSA-P. It has been shown that imaging of neuronal activity, as determined by metabolism or perfusion, can also help distinguish PD from MSA-P. We investigated whether the differential diagnostic value of (11)C-raclopride PET could be improved by dynamic scan analysis combining D2R binding and regional tracer influx.
METHODS: (11)C-raclopride PET was performed in 9 MSA-P patients (mean age +/- SD, 56.2 +/- 10.2 y; disease duration, 2.9 +/- 0.8 y; median Hoehn-Yahr score, 3), 10 PD patients (mean age +/- SD, 65.7 +/- 8.1 y; disease duration, 3.3 +/- 1.5 y; median Hoehn-Yahr score, 1.5), and 10 healthy controls (mean age +/- SD, 61.6 +/- 6.5 y). Diagnosis was obtained after prolonged follow-up (MSA-P, 5.5 +/- 2.0 y; PD, 6.0 +/- 2.3 y) using validated clinical criteria. Spatially normalized parametric images of binding potential (BP) and local influx ratio (R(1) = K(1)/K'(1)) of (11)C-raclopride were obtained using a voxelwise reference tissue model with occipital cortex as reference region. Stepwise forward discriminant analysis with cross-validation, with and without the inclusion of regional R(1) values, was performed using a predefined volume-of-interest template.
RESULTS: Using conventional BP values, we correctly classified 65.5% (all values given with cross-validation) of 29 cases only. The combination of BP and R(1) information increased discrimination accuracy to 79.3%. When healthy controls were not included and patients only were considered, BP information alone discriminated PD and MSA-P in 84.2% of cases, but the combination with R(1) data increased accuracy to 100%.
CONCLUSION: Discriminant analysis using combined striatal D2R BP and cerebral influx ratio information of a single dynamic (11)C-raclopride PET scan distinguishes MSA-P and PD patients with high accuracy and is superior to conventional methods of striatal D2R binding analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237023     DOI: 10.2967/jnumed.109.070144

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy.

Authors:  Yu Wang; Aneeka M Hancock; Joshua Bradner; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Karen L Edwards; Katherine W Snapinn; David S Goldstein; Min Shi; Jing Zhang
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

2.  Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.

Authors:  Liping Fu; Linwen Liu; Jinming Zhang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

Review 3.  The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

4.  Differences in dopaminergic modulation to motor cortical plasticity between Parkinson's disease and multiple system atrophy.

Authors:  Shoji Kawashima; Yoshino Ueki; Tatsuya Mima; Hidenao Fukuyama; Kosei Ojika; Noriyuki Matsukawa
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

5.  Dynamic 18F-FPCIT PET: Quantification of Parkinson's disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session.

Authors:  Shichun Peng; Chris Tang; Katharina Schindlbeck; Yaacov Rydzinski; Vijay Dhawan; Phoebe G Spetsieris; Yilong Ma; David Eidelberg
Journal:  J Nucl Med       Date:  2021-03-19       Impact factor: 11.082

6.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

7.  Comparison of PET template-based and MRI-based image processing in the quantitative analysis of C11-raclopride PET.

Authors:  Felix P Kuhn; Geoffrey I Warnock; Cyrill Burger; Katharina Ledermann; Chantal Martin-Soelch; Alfred Buck
Journal:  EJNMMI Res       Date:  2014-01-22       Impact factor: 3.138

Review 8.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Flavia Niccolini; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-28       Impact factor: 9.236

Review 9.  Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Authors:  Usman Saeed; Jordana Compagnone; Richard I Aviv; Antonio P Strafella; Sandra E Black; Anthony E Lang; Mario Masellis
Journal:  Transl Neurodegener       Date:  2017-03-28       Impact factor: 8.014

10.  Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission.

Authors:  Maarten Ooms; Sofie Celen; Ronald De Hoogt; Ilse Lenaerts; Johnny Liebregts; Greet Vanhoof; Xavier Langlois; Andrey Postnov; Michel Koole; Alfons Verbruggen; Koen Van Laere; Guy Bormans
Journal:  EJNMMI Radiopharm Chem       Date:  2016-03-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.